Cited 0 times in Scipus Cited Count

Efficacy and safety of mepolizumab in korean patients with severe eosinophilic asthma from the dream and mensa studies

DC Field Value Language
dc.contributor.authorKim, MK-
dc.contributor.authorPark, HS-
dc.contributor.authorPark, CS-
dc.contributor.authorMin, SJ-
dc.contributor.authorAlbers, FC-
dc.contributor.authorYancey, SW-
dc.contributor.authorMayer, B-
dc.contributor.authorKwon, N-
dc.date.accessioned2023-01-05T03:03:07Z-
dc.date.available2023-01-05T03:03:07Z-
dc.date.issued2021-
dc.identifier.issn1226-3303-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23618-
dc.description.abstractBackground/Aims: The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. Methods: Data from Korean patients in the Phase III, placebo-controlled, randomised DREAM (MEA112997/NCT01000506) and MENSA (MEA115588/ NCT01691521) studies were included. Patients ≥ 12 years old with severe eosinophilic asthma received mepolizumab (DREAM: 75, 250 or 750 mg intravenously [IV]; MENSA: 75 mg IV or 100 mg subcutaneously [SC]), or placebo every 4 weeks for 52 weeks (DREAM) or 32 weeks (MENSA). The primary outcome was the rate of clinically significant asthma exacerbations. Secondary outcomes included forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) and St George’s Respiratory Questionnaire (SGRQ) scores (MENSA only). Blood eosinophil counts (BEC) and safety were assessed throughout. Results: Reductions in the rate of clinically significant asthma exacerbations were observed with the approved (100 mg SC) and bioequivalent (75 mg IV) doses of mepolizumab in Korean patients who participated in DREAM and MENSA. In MENSA, trends for improvements from baseline at week 32 in pre-bronchodilator FEV1 (75 mg IV group), ACQ-5 and SGRQ scores (in both treatment groups) were seen versus placebo in Korean patients. Incidence of on-treatment adverse events was similar in Korean patients versus non-Korean patients as were observed reductions from baseline in BEC. Conclusions: Mepolizumab treatment provided clinical benefits for Korean patients with severe eosinophilic asthma; the safety profile is consistent with the overall population.-
dc.language.isoen-
dc.subject.MESHAnti-Asthmatic Agents-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAsthma-
dc.subject.MESHChild-
dc.subject.MESHHumans-
dc.subject.MESHRepublic of Korea-
dc.titleEfficacy and safety of mepolizumab in korean patients with severe eosinophilic asthma from the dream and mensa studies-
dc.typeArticle-
dc.identifier.pmid32450626-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969054/-
dc.subject.keywordAsthma-
dc.subject.keywordRepublic of Korea-
dc.subject.keywordSymptom flare up-
dc.subject.keywordTherapeutics-
dc.contributor.affiliatedAuthorPark, HS-
dc.type.localJournal Papers-
dc.identifier.doi10.3904/KJIM.2019.198-
dc.citation.titleThe Korean journal of internal medicine-
dc.citation.volume36-
dc.citation.number2-
dc.citation.date2021-
dc.citation.startPage362-
dc.citation.endPage370-
dc.identifier.bibliographicCitationThe Korean journal of internal medicine, 36(2). : 362-370, 2021-
dc.identifier.eissn2005-6648-
dc.relation.journalidJ012263303-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Allergy
Files in This Item:
32450626.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse